Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — H.C. Wainwright 24th Annual Global Investment Conference 2022
15 slides from Clinuvel Pharmaceuticals's conference presentation, Sep 13, 2022
Slide 1: Diversified Specialised Pharmaceutical
For personal use only Diversified Specialised Pharmaceutical H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 ASX: CUV Presented by: Malcolm Bull XETRA-DAX: UR9 Level 1 ADR: CLVLY clinuvel.com Head of Australian Operations news.clinuvel.com and Investor Relations
Slide 2: Forward-Looking Statements
Forward-Looking This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could Statements cause our future results, performance or achievements to differ significantl
Slide 3: Mission & Objectives
Mission & Objectives CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Establishing a specialised pharmaceutical group - diversified and vertically integrated to serve unmet medical and healthcare needs We provide a safe and acco
Slide 4: CLINUVEL Group Functional Divisions
CLINUVEL Group Functional Divisions CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Pharmaceutical Healthcare Solutions Communications, Branding & Marketing Manufacturing R&D + Commercial Translational science to Establishing &
Slide 5: Proven Technology
CLINUVEL Group Proven Technology CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only 1. SCENESSE® (afamelanotide 16mg) • Synthetic peptide, mimics biological α-MSH • First systemic photoprotective (Rx) for erythropoietic protoporph
Slide 6: SCENESSE® Systemic Photoprotection in EPP
SCENESSE® Systemic Photoprotection in EPP CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Ongoing Commercial Operations: EU, CH, IS, US EEA launched June 2016 US launched April 2020 • Six financial years of post-authorisation •
Slide 7: Financial Discipline: From R&D to Commercial
Financial Discipline From R&D to Commercial (since June 2016) CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only 80 60 40 A$m 20 0 -20 -40 FY2005 FY2006 FY2007 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017
Slide 8: Six Year Performance
Six Year Performance Growth in revenues, and by controlling expenses, one has arrived at…… ….. a strong balance sheet and………………………………….. CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only 80 25 150 60 20 125 40 100 15 20 75 A$m 10
Slide 9: EPP Therapeutic Landscape
EPP Therapeutic Landscape CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only SCENESSE® - The Standard of Care in EPP “Competition whose • Safety profile accumulated since 2006 in EPP patients motive is merely to • Approx. 12,000 d
Slide 10: CLINUVEL's Strategic Path
CLINUVEL’s Strategic Path Multi-pronged Strategy CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Expansion strategy 1. Portfolio of Melanocortins (Rx): • Translation afamelanotide to multiple indications • ACTH in development •
Slide 11: Specialised Pharmaceutical Portfolio of Melanocortins
Specialised Pharmaceutical Portfolio of Melanocortins CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Afamelanotide – Photoprotective, Repigmentation, Anti-Oxidative, Anti-Oncotic, DNA Repair SCENESSE® (afamelanotide 16mg) Impl
Slide 12: Clinical Development
Clinical Development Targeting Several Identified Patient Populations with Afamelanotide CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only DNA Repair Vitiligo Arterial Variegate New Indication Ischaemic Stroke Porphyria CUV156 CU
Slide 13: Healthcare Solutions Program: Dermatocosmetics
Healthcare Solutions Program Dermatocosmetics CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only 1. Translation of Technology 2. Melanocortin Molecules Establishment of Division of Use in non-prescription products Healthcare Solut
Slide 14: Summary
CLINUVEL Group Summary CLINUVEL Group • H. C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 For personal use only Six Consecutive Annual Profits to FY2022 Expect • First in class treatment SCENESSE® • Read-outs on Xeroderma • Strong annual demand Pigmentosum (DNA-repair
Slide 15: Thank you for your invitation
For personal use only Thank you for your invitation ASX: CUV Presented by: Malcolm Bull XETRA-DAX: UR9 Level 1 ADR: CLVLY clinuvel.com Head of Australian Operations news.clinuvel.com and Investor Relations Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTIALS LTD
CLINUVEL Pharmaceuticals — H.C. Wainwright 24th Annual Global Investment Conference 2022 on 6ix